GLP-1 medications in California: Medicaid coverage, provider availability and real cost
California: telehealth prescribing, pharmacy licensing, and Medicaid
California requires a good-faith exam before prescribing, satisfiable via synchronous telehealth. The California State Board of Pharmacy licenses nonresident pharmacies shipping into California. Medi-Cal ended GLP-1 coverage for obesity on January 1, 2026; coverage continues for type 2 diabetes and some other indications with prior authorization.
Verify current rules with the California Board of Medicine and California Board of Pharmacy before enrolling; telehealth and coverage rules change. Last reviewed July 2026.
What California Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a California resident.
What we evaluated: California Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; September 4, 2026 for provider pricing
Direct answer: California Medicaid eliminated GLP-1 coverage for obesity on 1 January 2026. If you were relying on it, you are now a cash-pay patient. Oak Longevity ($133 a month on our September 4, 2026 capture) is NOT available here. Mondae ($87) and Eden Health ($99) list the lowest standing month-to-month compounded semaglutide prices in our index with no membership (read October 15, 2026; confirm a program serves your state); NexLife's is $109 a month month to month and $95 a month on a 12-month plan (as of November 6, 2026); the 22 compounded semaglutide programs in our index publish lowest all-in prices from $49 to $169 a month, median $94 (competitor reads dated October 15, 2026 or earlier). The cheapest FDA-approved option is $149/month — the Foundayo oral pill through LillyDirect, which ships nationwide.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Medi-Cal: GLP-1 coverage in California
Diabetes coverage continues; obesity coverage does not.
Medi-Cal eliminated GLP-1 coverage for obesity effective 1 January 2026 to reduce pharmacy spending, after spending on weight-loss-indicated GLP-1s roughly quadrupled between early 2024 and mid-2025. Coverage for diabetes continues. Medi-Cal has confirmed that Wegovy for noncirrhotic MASH remains covered where the prescriber submits the appropriate diagnosis code.
The need in California, and the coverage gap
California eliminated Medicaid coverage for obesity GLP-1s on 1 January 2026. The need did not fall on 1 January 2026. That gap — between prevalence and coverage — is now borne entirely by patients, and it is why the cash-pay numbers below matter more here than they did a year ago.
Which providers serve California
| Provider | Status in CA | Compared with | What it means for you |
|---|---|---|---|
| bmiMD | $379.99 | vs $289 elsewhere | State surcharge on our September 4, 2026 capture; confirm at checkout |
| Oak Longevity | Not available | — | Oak Longevity does not serve California |
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
Prices available in California
The Wegovy pill costs $149 a month at 1.5 mg through NovoCare (read Oct 15, 2026), above the $94 median of our 22-program compounded semaglutide index; what the extra money buys is an FDA-approved product with its own trials.
The dated change in California
Wegovy, Zepbound and Saxenda were removed from the Medi-Cal Rx Contract Drugs List for obesity. All prior authorisations for weight-loss indications ended December 31, 2025. Coverage continues for type 2 diabetes, cardiovascular disease and sleep apnea with PA. Medi-Cal explicitly confirmed Wegovy for MASH remains covered with the correct diagnosis code. Members under 21 retain access under federal EPSDT. Denials can be appealed by requesting a State Hearing within 90 days.
Source: Medi-Cal Rx Contract Drugs List; KFF, January 2026.
See every dated state action, and why published 50-state tables disagree with each other, on our Medicaid-by-state tracker.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in California?
ELIMINATED coverage on 1 January 2026. Diabetes coverage continues; obesity coverage does not. Coverage for type 2 diabetes is separate and is available in every state.
Which GLP-1 telehealth providers serve California?
Oak Longevity — the cheapest compounded semaglutide in our set at $133 — is NOT available in California. On this site's September 4, 2026 capture, bmiMD listed a higher price for California residents ($379.99 vs $289); we have not re-checked the state surcharge since. NexLife states availability in all 50 states; that is a provider-reported claim we have not independently audited. MEDVi serves 49 states and does not publish which one is excluded. LillyDirect and NovoCare ship nationwide.
What is the cheapest GLP-1 option in California?
the cheapest FDA-approved option is $149/month (Foundayo oral, via LillyDirect). Mondae ($87) and Eden Health ($99) list the lowest standing month-to-month compounded semaglutide prices in our index with no membership (read October 15, 2026; confirm a program serves your state); NexLife's is $109 a month month to month and $95 a month on a 12-month plan (as of November 6, 2026); Oak Longevity is unavailable in California.
I'm under 21 and was denied. Is that final?
No. Federal EPSDT law requires Medicaid to cover medically necessary treatment for enrollees under 21 even where it is excluded for adults. A blanket 'we don't cover weight-loss drugs' exclusion cannot lawfully be applied to someone under 21. Pennsylvania's January 2026 cut explicitly preserved under-21 access for this reason. That denial is appealable.
How do I verify a compounding pharmacy is licensed in California?
The California Board of Pharmacy maintains a licensee database — that is the primary source, and it is public. Ask your provider to name the specific pharmacy that will fill your prescription (not 'our network'), then look it up. A provider that will not name its pharmacy has told you something.
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- California Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, September 4, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed September 4, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Made with the drug in Wegovy and Ozempic, not the same product — and the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.